Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 11, 2015, Pages 1863-1869

  Majhail, Navneet S ^a   Farnia, Stephanie H ^b   Carpenter, Paul A ^c   Champlin, Richard E ^d   Crawford, Stephen ^e   Marks, David I ^f   Omel, James L ^g   Orchard, Paul J ^h   Palmer, Jeanne ⁱ   Saber, Wael ^j   Savani, Bipin N ^k   Veys, Paul A ^l   Bredeson, Christopher N ^m   Giralt, Sergio A ⁿ   LeMaistre, Charles F ^o  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Payer Policy   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Cigna   (United States)

^f UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^g Grand Island   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ MAYO CLINIC   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o Sarah Cannon Cancer Institute   (United States)

more..

Author keywords

Allogeneic transplantation; Autologous transplantation; Clinical trials; Hematopoietic cell transplantation; Indications; Routine care; Standard of care

Indexed keywords

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEALTH CARE QUALITY; HUMAN; MEDICAL SOCIETY; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; RARE DISEASE; SURVIVAL; TREATMENT INDICATION; UNITED STATES; ADULT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL (TOPIC); HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOLOGY; RARE DISEASES;

ADULT; AGE FACTORS; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RARE DISEASES; SOCIETIES, MEDICAL; STANDARD OF CARE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 84943452957     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.032     Document Type: Article

References (44)

1. Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR summary slides. Retrieved from http://www.cibmtr.org.
2. Majhail N.S., Murphy E.A., Denzen E.M., et al. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. Biol Blood Marrow Transplant 2012, 18:172-182.
3. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
4. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013, 31:2437-2449.
5. Majhail N.S., Tao L., Bredeson C., et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant 2013, 19:1498-1501.
6. McCarthy P.L., Hahn T., Hassebroek A., et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013, 19:1116-1123.
7. LeMaistre C.F., Farnia S., Crawford S., et al. Standardization of terminology for episodes of hematopoietic stem cell patient transplant care. Biol Blood Marrow Transplant 2013, 19:851-857.
8. Majhail N.S., Giralt S., Bonagura A., et al. Guidelines for defining and implementing standard episode of care for hematopoietic stem cell transplantation within the context of clinical trials. Biol Blood Marrow Transplant 2015, 21:583-588.
9. British Society of Blood and Marrow Transplantation indications table. Available at: Accessed February 1, 2015. http://bsbmt.org/indications-table/.
10. Sureda A., Bader P., Cesaro S., et al. Indications for allo- and auto-SCT for haematological diseases, solid tumors and immune disorders: Current practice in Europe, 2015. Bone Marrow Transplant 2015, 50:1037-1056.
11. NCCN Guidelines and Clinical Resources: NCCN categories of evidence and consensus. Available at: Accessed February 1, 2015. http://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp.
12. Oliansky D.M., Rizzo J.D., Aplan P.D., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007, 13:1-25.
13. Oliansky D.M., Appelbaum F., Cassileth P.A., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2008, 14:137-180.
14. Oliansky D.M., Antin J.H., Bennett J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009, 15:137-172.
15. Oliansky D.M., Gordon L.I., King J., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010, 16:443-468.
16. Oliansky D.M., Czuczman M., Fisher R.I., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011, 17:20-47.
17. Oliansky D.M., Camitta B., Gaynon P., et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant 2012, 18:505-522.
18. Oliansky D.M., Larson R.A., Weisdorf D., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant 2012, 18:16-17.
19. Shah N., Callander N., Ganguly S., et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015, 21:1155-1166.
20. Perales M.A., Ceberio I., Armand P., et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015, 21:971-983.
21. National Marrow Donor Program/Be The Match and ASBMT Referral Guidelines: Recommended timing for transplant consultation, 2015. Retrieved from and http://BeTheMatchClinical.org/guidelines.
22. Gragert L., Eapen M., Williams E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014, 371:339-348.
23. Zhang M.J., Davies S.M., Camitta B.M., et al. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012, 18:1204-1210.
24. Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012, 119:3908-3916.
25. Saber W., Cutler C.S., Nakamura R., et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood 2013, 122:1974-1982.
26. Eapen M., Rubinstein P., Zhang M.J., et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006, 24:145-151.
27. Schetelig J., Bornhauser M., Schmid C., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008, 26:5183-5191.
28. Valcarcel D., Sierra J., Wang T., et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant 2011, 17:640-648.
29. Gupta V., Tallman M.S., He W., et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010, 116:1839-1848.
30. Walter R.B., Pagel J.M., Gooley T.A., et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010, 24:1276-1282.
31. Peters C., Schrappe M., von Stackelberg A., et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol 2015, 33:1265-1274.
32. Weisdorf D., Eapen M., Ruggeri A., et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord analysis. Biol Blood Marrow Transplant 2014, 20:816-822.
33. Marks D.I., Woo K.A., Zhong X., et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014, 99:322-328.
34. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
35. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
36. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
37. Luo Y., Xiao H., Lai X., et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 2014, 124:2735-2743.
38. Wang Y., Liu Q.F., Xu L.P., et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015, 125:3956-3962.
39. Solomon S.R., Sizemore C.A., Sanacore M., et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015, 21:1299-1307.
40. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013, 31:1310-1316.
41. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
42. Michaelis L.C., Hamadani M., Hari P.N. Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. Exp Rev Hematol 2014, 7:321-324.
43. McClune B.L., Weisdorf D.J. Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?. Curr Opin Hematol 2010, 17:133-138.
44. Wildes T.M., Stirewalt D.L., Medeiros B., Hurria A. Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Comprehen Cancer Netw 2014, 12:128-136.